Showing results (1-10 of 49) with videos related to
Sort By:
Pageof 5
Hematology/Oncology and Stem Cell Therapy|June 4, 2019
Updates in prognostication and treatment of Waldenström's macroglobulinemiaPooja Advani, Aneel Paulus, Sikander AilawadhiCancers|July 27, 2022
Updates in the Use of BCL-2-Family Small Molecule Inhibitors for the Treatment of Relapsed/Refractory Multiple MyelomaRicardo D Parrondo, Aneel Paulus, Sikander AilawadhiLeukemia & Lymphoma|August 17, 2022
CD38 as a multifaceted immunotherapeutic target in CLLAneel Paulus, Fabio Malavasi, Asher Chanan-KhanBest Practice & Research. Clinical Haematology|November 10, 2016
Preclinical models of Waldenström's macroglobulinemia and drug resistanceSikander Ailawadhi, Aneel Paulus, Asher Chanan-KhanBest Practice & Research. Clinical Haematology|November 10, 2016
Novel therapeutic targets in Waldenstrom macroglobulinemiaAneel Paulus, Sikander Ailawadhi, Asher Chanan-KhanExpert Opinion on Drug Metabolism & Toxicology|April 28, 2011
Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemiaPooja P Advani, Aneel Paulus, Ayesha Masood, et al.Drug Safety|July 15, 2026
Safety and Management of Targeted Therapies for Relapsed/Refractory Chronic Lymphocytic LeukemiaSikander Ailawadhi, Elcin Omercikoglu, Aneel Paulus, et al.Oncotargets and Therapy|December 14, 2011
Targeted treatment for chronic lymphocytic leukemiaAisha Masood, Taimur Sher, Aneel Paulus, et al.Molecules (Basel, Switzerland)|October 24, 2020
The Circular Life of Human CD38: From Basic Science to Clinics and BackAlberto L Horenstein, Angelo C Faini, Fabio Morandi, et al.Leukemia & Lymphoma|June 20, 2020
Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibitor display anti-tumor activity in a xenograft model of bortezomib-resistant Waldenstrom macroglobulinemiaVijay Sagar Madamsetty, Aneel Paulus, Sharoon Akhtar, et al.Pageof 5